Cargando…

SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis

Metabolic reprogramming, such as alterations in glutamine metabolism or glycolysis, is the hallmark of hepatocellular carcinoma (HCC). However, the underlying mechanisms are still incompletely elucidated. Previous studies have identified that methyltransferase SET and MYND domain-containing protein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Kangdi, Ding, Jun, Zhou, Lingfeng, Li, Dazhi, Luo, Jia, Wang, Wenchao, Shang, Mingge, Lin, Bingyi, Zhou, Lin, Zheng, Shusen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818721/ https://www.ncbi.nlm.nih.gov/pubmed/36611819 http://dx.doi.org/10.3390/cells12010025

Ejemplares similares

Overexpression of CXCL2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma
por: Ding, Jun, et al.
Publicado: (2018)

The Epithelial to Mesenchymal Transition Promotes Glutamine Independence by Suppressing GLS2 Expression
por: Ramirez-Peña, Esmeralda, et al.
Publicado: (2019)

Glutamine metabolic reprogramming in hepatocellular carcinoma
por: Ye, Yanyan, et al.
Publicado: (2023)

MYC-induced reprogramming of glutamine catabolism supports optimal virus replication
por: Thai, Minh, et al.
Publicado: (2015)

GLS2 shapes ferroptosis in hepatocellular carcinoma
por: Suzuki, Sawako, et al.
Publicado: (2023)

ACSL4 promotes hepatocellular carcinoma progression via c-Myc stability mediated by ERK/FBW7/c-Myc axis
por: Chen, Junru, et al.
Publicado: (2020)

m5C-methylated lncRNA NR_033928 promotes gastric cancer proliferation by stabilizing GLS mRNA to promote glutamine metabolism reprogramming
por: Fang, Lang, et al.
Publicado: (2023)

Circ_0000003 regulates glutamine metabolism and tumor progression of tongue squamous cell carcinoma via the miR-330-3p/GLS axis
por: Qian, Cuijuan, et al.
Publicado: (2021)

Targeting YTHDF1 effectively re-sensitizes cisplatin-resistant colon cancer cells by modulating GLS-mediated glutamine metabolism
por: Chen, Ping, et al.
Publicado: (2021)

Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer
por: Saha, Subbroto Kumar, et al.
Publicado: (2019)

Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma
por: Binh, Mai Thanh, et al.
Publicado: (2020)

Silencing of GLS and overexpression of GLS2 genes cooperate in decreasing the proliferation and viability of glioblastoma cells
por: Szeliga, Monika, et al.
Publicado: (2013)

MYC regulation of glutamine–proline regulatory axis is key in luminal B breast cancer
por: Craze, Madeleine L, et al.
Publicado: (2018)

GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy
por: Mukha, Anna, et al.
Publicado: (2021)

Kidney-type glutaminase (GLS1) is a biomarker for pathologic diagnosis and prognosis of hepatocellular carcinoma
por: Yu, Decai, et al.
Publicado: (2015)

Del11q-positive CLL lymphocytes exhibit altered glutamine metabolism and differential response to GLS1 and glucose metabolism inhibition
por: Galicia-Vázquez, Gabriela, et al.
Publicado: (2018)

Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis
por: Bagislar, Sevgi, et al.
Publicado: (2016)

Selenite inhibits glutamine metabolism and induces apoptosis by regulating GLS1 protein degradation via APC/C-CDH1 pathway in colorectal cancer cells
por: Zhao, Junzhang, et al.
Publicado: (2016)

SOCS1 blocks G1-S transition in hepatocellular carcinoma by reducing the stability of the CyclinD1/CDK4 complex in the nucleus
por: Ding, Jun, et al.
Publicado: (2020)

ANKHD1 is required for SMYD3 to promote tumor metastasis in hepatocellular carcinoma
por: Zhou, Zhenyu, et al.
Publicado: (2019)

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Wang, Shanshan, et al.
Publicado: (2023)

SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters
por: Zhang, Heyun, et al.
Publicado: (2021)

Hispidin Inhibits Ferroptosis Induced by High Glucose via the miR-15b-5p/GLS2 Axis in Pancreatic Beta Cells
por: Wu, Fang, et al.
Publicado: (2023)

Correction: SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters
por: Zhang, Heyun, et al.
Publicado: (2021)

Regulation of Cardiac Fibroblast GLS1 Expression by Scleraxis
por: Chattopadhyaya, Sikta, et al.
Publicado: (2022)

Smyd3-PARP16 axis accelerates unfolded protein response and vascular aging
por: Yang, Di, et al.
Publicado: (2020)

Long non-coding RNA00844 inhibits MAPK signaling to suppress the progression of hepatocellular carcinoma by targeting AZGP1
por: Lin, Bingyi, et al.
Publicado: (2020)

c‐Myc–IMPDH1/2 axis promotes tumourigenesis by regulating GTP metabolic reprogramming
por: Zhang, Qiang, et al.
Publicado: (2023)

GLS as a diagnostic biomarker in breast cancer: in-silico, in-situ, and in-vitro insights
por: Zhang, Danfeng, et al.
Publicado: (2023)

Key Roles of Glutamine Pathways in Reprogramming the Cancer Metabolism
por: Michalak, Krzysztof Piotr, et al.
Publicado: (2015)

miR-22 Suppresses EMT by Mediating Metabolic Reprogramming in Colorectal Cancer through Targeting MYC-Associated Factor X
por: Xia, Shusen, et al.
Publicado: (2022)

In vivo Reprogramming of Cancer Metabolism by MYC
por: Camarda, Roman, et al.
Publicado: (2017)

Inhibition of GLS suppresses proliferation and promotes apoptosis in prostate cancer
por: Zhang, Junfeng, et al.
Publicado: (2019)

Antagonistic effects of MYC and hypoxia in channeling glucose and glutamine into de novo nucleotide biosynthesis
por: Fan, Teresa, et al.
Publicado: (2014)

MicroRNA-424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation
por: Wu, Liming, et al.
Publicado: (2018)

SMYD3–PARP16 axis accelerates unfolded protein response and mediates neointima formation
por: Long, Fen, et al.
Publicado: (2021)

Positive Expression of SMYD2 is Associated with Poor Prognosis in Patients with Primary Hepatocellular Carcinoma
por: Zuo, Shan-Ru, et al.
Publicado: (2018)

HepaCAM-PIK3CA axis regulates the reprogramming of glutamine metabolism to inhibit prostate cancer cell proliferation
por: He, Zhenting, et al.
Publicado: (2022)

HJURP Promotes Epithelial-to-Mesenchymal Transition via Upregulating SPHK1 in Hepatocellular Carcinoma
por: Chen, Tianchi, et al.
Publicado: (2019)

Single Nucleotide Polymorphisms in the Metastasis-associated in Colon Cancer-1 Gene Predict the Recurrence of Hepatocellular Carcinoma after Transplantation
por: Zheng, Zhiyun, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f2e1o7c4a6n35qesuk4j94edg5